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ABSTRACT 
 Human mitochondrial NAD kinase is a crucial enzyme responsible for the 
synthesis of mitochondrial NADP+. Despite its significance, little is known about the 
regulation of this enzyme in the mitochondria. Several putative and known 
phosphorylation sites within the protein have been found using phosphoproteomics, and 
here, we examined the effect of phosphomimetic mutations at six of these sites. The 
enzymatic activity was downregulated by a substitution of an Asp residue at Ser-289 
and Ser-376, but not a substitution of Ala, suggesting that the phosphorylation of these 
residues downregulates the enzyme. Moreover, the activity was completely inhibited by 
substituting Ser-188 with an Asp, Glu, or in particular Ala, which highlights two 
possibilities: first, that Ser-188 is critical for catalytic activity, and second, that 
phosphorylation of Ser-188 inhibits the activity. Ser-188, Ser-289, and Ser-376 were 
found to be highly conserved in the primary structures of mitochondrial NAD kinase 
homologs in higher animals. Moreover, Ser-188 has been frequently detected in human 
and mouse phosphorylation site studies, whereas Ser-289 and Ser-376 have not. Taken 
together, this indicates that Ser-188 (and perhaps the other residues) is an important 
phosphorylation site that can downregulate the NAD kinase activity of this critical 
enzyme. 
 





 NADP (NADP+ and its reduced form NADPH) is involved in anabolic 
reactions, as well as in the defense against oxidative stress. It also functions as a 
substrate in the synthesis of NAADP, a potent intracellular calcium messenger [1,2]. 
NAD kinase (NADK; EC 2.7.1.23), the sole NADP+-biosynthetic enzyme known to 
catalyze the phosphorylation of NAD+ into NADP+ using ATP, plays a vital role in the 
cell. There are two types of NADK in human cells: cytosolic NADK (cytNADK) 
[3,4,5,6] and mitochondrial NADK (mitNADK) [7,8,9], with mitNADK having a much 
lower Km (for NAD+, 22 µM) and activity (Vmax, 0.091 U/mg) than cytNADK (Km for 
NAD+, 1.07 mM; Vmax, 18.5 U/mg) [7]. A homozygous nonsense mutation in the gene 
encoding the human mitNADK causes dienoyl-CoA reductase deficiency with 
hyperlysinemia and a failure to thrive [9], emphasizing the critical role of mitNADK. 
Despite the importance of both NADKs, little is known about how they are regulated in 
vivo.  
 Phosphorylation is a widespread mechanism for controlling the function of 
enzymes. Recently, Love et al. reported that the N-terminal portion, in particular Ser-64, 
of human cytNADK is phosphorylated in a Ca2+/CaM-dependent manner [4]. However, 
recombinant purified cytNADK mutants with a phosphomimetic (S64D) or a 
phosphoresistant (S64A) amino-acid substitution at Ser-64 have similar levels of 
enzymatic activity [4]. Moreover, in vitro phosphorylation of wild-type and S64A 
cytNADK does not change catalytic activity [4]. Therefore, the physiological role of 
 4 
human cytNADK phosphorylation remains to be clarified.  
 Mitochondria are the major sites of reactive oxygen species (ROS) generation, 
and mitochondrial ROS levels are tightly regulated, because they have critical roles in 
the adaptation to hypoxia, autophagy, immunity, differentiation, and probably aging 
[10]. Because NADPH also participates in the regulation of mitochondrial ROS levels 
[10], the function of mitNADK is most likely tightly regulated in mitochondria in 
response to intracellular and extracellular signals. Phosphoproteomics has revealed 
several phosphorylation sites in mitNADK from humans [11,12,13], mice [14,15,16], 
and rats [17,18], which are summarized in PhosphoSitePlus (Q4G0N4, 
http://www.phosphosite.org) (Fig. 1, Table 1).  
 To elucidate the role of human mitNADK phosphorylation, we introduced 
several phosphomimetic amino-acid substitutions into human mitNADK and measured 
the NADK activity of the purified enzymes. We expected that a few of the 
phosphomimetic mutations would increase activity, because the activity of mitNADK is 
very low relative to that of cytNADK [7]. However, we found that two phosphomimetic 
mutations at Ser-289 and Ser-376 downregulated activity and one at Ser-188 abolished 
its activity altogether, implying that these phosphorylation events actually downregulate 
this enzyme in mitochondria.  
 
2. Materials and methods 
 
2.1. Plasmid and expression 
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 Phosphomimetic and phosphoresistant mitNADKs were constructed with 
PCR using pMK3272 as a template. pMK3272 is the expression plasmid pQE-80L 
(Qiagen, Venlo, Netherlands) carrying a human mitNADK gene [7]. This gene encodes 
Δ62mitNADK, which lacks the 62 N-terminal amino acids including the mitochondrial 
targeting sequence [7] (Fig. 1). The expression of wild-type, phosphomimetic 
(substitution of Ser to Asp or Glu), and phosphoresistant (substitution of Ser to Ala) 
mitNADK was conducted as described [7]. Δ62mitNADK is expressed from pMK3272 
as an N-terminal His-Tag (1MRGSHHHHHHGS12)–fusion protein. Purification of the 
expressed protein was performed using a TALON Metal Affinity Resin column 
(Clontech, Otsu, Japan) [7]. Washing was done with 10 mM Tris-HCl (pH 8.0), 300 
mM NaCl, and 30 mM neutralized imidazole, and elution was done with 10 mM 
Tris-HCl (pH 8.0), 300 mM NaCl, and 150 mM neutralized imidazole. The fractions 




 NADK activity was assayed at 37°C by the continuous method and the stop 
method, as described previously [7]. Briefly, NADPH formation was continuously 
measured at A340 in a reaction mixture (1.0 mL) containing 5.0 mM NAD+, 5.0 mM 
ATP, 5.0 mM glucose 6-phosphate, 0.5 U glucose 6-phosphate dehydrogenase (Sigma, 
St. Louis, MD), 5 mM MgCl2, 100 mM Tris-HCl (pH 8.0), and an appropriate 
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concentration of purified protein. In the stop method, glucose 6-phosphate 
dehydrogenase was diluted with 50% glycerol to reduce background. One unit of 
enzyme activity was defined as 1.0 µmol NADP+ produced in 1 min at 37°C; specific 
activity was expressed in U/mg protein, unless otherwise stated. The protein 
concentration of the purified Δ62mitNADK and its mutants was determined using A280 
and a molecular coefficient that was calculated using the ExPASy ProtParam tool [19]. 
The molecular mass of Δ62mitNADK (plus the N-terminal His-Tag) is 44,726.4, and 
the molecular coefficient is 50,880 M-1 cm-1 (Δ62mitNADK of A280 = 1.138 
corresponds to 1 mg/ml). 
 
2.3. Circular dichroism (CD)  
 
 The purified mitNADK (wild type), phosphomimetic mitNADK (S188D), and 
phosphoresistant mitNADK (S188A) were dialyzed against 10 mM Tris-HCl (pH 8.0) 
containing 300 mM NaCl. This dialysis external solution was prepared with ultra-pure 
water. CD of the purified enzyme was analyzed with a CD spectrometer (J-720 
Spectropolarimeter, Jasco, Tokyo, Japan). The control was 10 mM Tris-HCl (pH 8.0) 
containing 300 mM NaCl. Conditions were as follows: protein concentrations, 
0.1–0.2 mg/ml; quartz cell length, 0.01 cm; scan range, 190–260 nm; resolution, 
0.1 nm; band length, 1 nm; scan speed, 10 nm/min; cumulative number, 3 times; and 
sample volume, 65 µL.  
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3. Results and discussion 
 
3.1. Activity of phosphomimetic mitNADK proteins 
 
 Phosphoproteomics has reveled several phosphorylation sites within the 
mitNADK of humans [11,12,13], mice [14,15,16], and rats [17,18], which are 
summarized in PhosphoSitePlus (Q4G0N4, http://www.phosphosite.org) (Fig. 1, Table 
1). Among the sites, we focused on Ser and Thr residues, especially on the residues that 
had been identified as phosphorylation sites in human mitNADK: Thr-183, Ser-188, 
Ser-345, and Ser-367 [11,12,13]. The detected count for Ser-188 was 207, whereas the 
counts for Ser-183, Ser-345, and Ser-367 were 6, 1, and 2 in the mass spectrometric 
analysis conducted by Bian et al. [11], implying that Ser-188 is relatively frequently 
phosphorylated. 
 We constructed expression plasmids for the human phosphomimetic 
mitNADK mutants T813D, S188D, S289D, S294D, S345D, T357D, S363D, S367D, 
and S376D. These mitNADK mutants were expressed in E. coli and purified (Fig. S1). 
The phosphomimetic mitNADK S188D, S289D, S345D, S363D, S367D, and S376D 
were successfully purified. Phosphomimetic mitNADK S183D failed to express, and 
two other mutants, T357D and S294D, were difficult to express in large quantity and to 
purify. 
 We expected that some phosphomimetic mutations would increase activity, 
because the activity of mitNADK is low relative to that of cytNADK [7]. However, the 
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activity of mitNADK S289D and S376D was lower than that of wild type, and the 
activity of mitNADK S188D was not detected, although mitNADK S363D, S345D, and 
S367D had the same activity as wild-type mitNADK (Fig. 2A). mitNADK S289E and 
S188E were also purified (Fig. S1). Again, the activity of mitNADK S289E was lower 
than that of wild type, and the activity of mitNADK S188E was not detected (Fig. 2A).  
 To rule out the possibility that Ser-289, Ser-376, and Ser-188 had a significant 
role in the catalytic activity itself, not in the regulation of the enzyme, we also 
constructed and purified phosphoresistant mitNADK S188A, S289A, and S376A (Fig. 
S2). The activity of mitNADK S376A was similar to that of wild type, whereas the 
activity of mitNADK S289A was 2-fold higher than that of the wild type (Fig. 2B), 
indicating that the phosphorylation of Ser-376 and Ser-289 reduces activity. The 
activity of mitNADK S188A was again not detected (Fig. 2B). The purified enzymes 
(wild-type mitNADK, mitNADK S188D, and mitNADK D188A) had approximately 
the same CD spectrum (Fig. S3), indicating that the substitutions of Asp or Ala into 
Ser-188 caused no noticeable structural change. These data highlight two possibilities: 
first, Ser-188 is critical for catalytic activity, and second, phosphorylation of Ser-188 
completely inhibits this activity.  
 
3.2. Conservation of the investigated Ser residues in the primary structure 
 
 NADKs can be roughly divided into two groups: human mitNADK homologs 
and human cytNADK homologs. Moreover, mitNADK homologs have sequence 
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similarity with plant NADK3 homologs and can be further divided into animal and 
protist mitNADK homologs [7]. The three key motifs (GGDG, NE/D, and NADK 
conserved motifs) are conserved in the three groups (mitNADK homologs, plant 
NADK3 homologs, and cytNADK homologs), and two motifs (motif 1/2 and the 
C5orf33 additional region) are not found in cytNADK homologs (Fig. 1) [7]. Thr-183 
and Ser-188 are found in motif 1/2, and the residues Ser-345, Thr-357, Tyr-360, and 
Ser-363 are located in the C5orf33 additional region that is specific to mitNADK 
homologs (Fig. 1).  
 The conservation of these residues in animal and protist mitNADK homologs 
and plant NADK3 homologs is listed in Table 2. Multiple alignments of the 
representative primary structures of mitNADK homologs are shown in Fig. S4. Thr-183, 
Ser-188, and Ser-289 are highly conserved in animal mitNADK homologs including 
mouse mitNADK and plant NADK3 homologs (Table 3). Ser-376 is highly conserved 
(100%) in the 62 mitNADK homologs from higher animals (mammals, birds, reptiles, 
and fishes). Thr-183 and Ser-188 are also found in protist mitNADK homologs from 
Apicomplexa including the genera Plasmodium, Theileria, and Babesia (Table 3). 
Earlier, we demonstrated that phosphomimetic mutation of the highly conserved 
Ser-188 abolished mitNADK activity, and mutation of the conserved Ser-376 and the 
highly conserved Ser-289 downregulated this activity (Fig. 2).  
 However, although Ser-183 and Ser-188 were frequently detected as 
phosphorylation sites, Ser-289 and Ser-376 were not; phosphorylation of Ser-183 and 
Ser-188 was detected in human mitNADK in two independent experiments [11,12,13]. 
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Phosphorylation of Ser-188 was detected in mouse mitNADK in three independent 
experiments [14,15,16], and the phosphorylation of Ser-183 was detected in mouse in 
one experiment [15]. However, phosphorylation of Ser-289 and Ser-376 was only 
detected once in mouse and rat mitNADKs, respectively (Table 1) [18]. Taken together, 
phosphorylation of Ser-188, and perhaps the other sites, could be a significant 
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Fig. 1. Putative and detected phosphorylation sites in human mitNADK 
[11,12,13,14,15,16,17,18], and the structures of NADK homologs. The residues studied 
here are in bold, and the residues that have been detected in human mitNADK with 
phosphoproteomics [11,12,13] are in italics (Thr-183, Ser-188, Ser-345, and Ser-367). 
Recombinant mitNADK (Δ62mitNADK) lacks the mitochondrial targeting sequence 
(Mit-seq, 62 residues) [7]. Primary structures of mitNADK homologs possess the 
GGDG motif, motif 1/2, the NE/D short motif, the NADK conserved motif (NADK), 
and the C5orf3 additional region (additional); in plant NADK3 homologs, only the 
additional region is not present (-), whereas in cytNADK homologs, motif 1/2 and the 
additional region are not present [7]. Note that plant NADK3 homologs have inserted 
sequence (NADK3 additional region consisting of 15 amino acids) between motif 1 and 












Table 1. The phosphorylation sites of mitNADK in human, mouse, and rata 







line / cell 
type / tissue 
Human  
  Thr-183 
  Ser-188 b 
  Ser-345 
  Ser-367 
 
  Thr-183 
  Ser-188 b 
  Ser-345 






  Thr-183 
  Ser-188 b 
  
 
  Thr-183 












  Ser-367   Ser-367 [13]  HeLa 
(cervical) 
Mouse 
  Ser-48 
  Ser-176 
 
  Ser-60 





  Ser-48 
  Thr-171 
  Ser-176 
  Ser-377 
 
  Ser-60 
  Thr-183 
  Ser-188 b 








  Ser-176 
 







  Ser-299 
  Tyr-300 
  Tyr-301 
  Ser-304 
 
  Ser-289 b 
  Tyr-290 
  Tyr-291 








  Ser-43 
 






  Thr-340 
  Tyr-343 
  Ser-346 
  Ser-359 
 
  Thr-357 
  Tyr-360 
  Ser-363 






a All sites were identified with mass spectrometry. 
b Phosphomimetic mutations at these sites downregulated human mitNADK (Fig. 2). 
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Table 2. Number of homologs in which the phosphorylation site in human mitNADK is 
conserved. a, b 
 117 animal mitNADK 
homologs c 
19 protist mitNADK 
homologs d 
50 plant NADK3 
homologs e 
Ser-60 16 (14%) 0 (0%) 0 (0%) 
Thr-183 f, i 108 (92%) 10 (53%) j 50 (100%) 
Ser-188 g, i 107 (91%) 10 (53%) j 50 (100%) 
Ser-289 g 104 (89%) 3 (16%) 50 (100%) 
Tyr-290 77 (66%) 0 (0%) 0 (0%) 
Tyr-291 76 (65%) 2 (11%) 4 (8%) 
Ser-294 67 (57%) 0 (0%) 46 (92%) 
Ser-345 h, i 32 (27%) 0 (0%) 0 (0%) 
Tyr-357 66 (56%) 7 (37%) 0 (0%) 
Tyr-360 65 (56%) 1 (5%) 0 (0%) 
Ser-363 h 68 (58%) 7 (37%) 0 (0%) 
Ser-367 h, i 46 (39%) 0 (0%) 0 (0%) 
Ser-376 g 66 (56%) k 0 (0%) 0 (0%) 
a The sites shown in Fig. 1. 
b Blast analysis [20] was conducted using the primary structure of human mitNADK as 
a query, and the obtained data was aligned using ClustalW [21].  
c, d, e The homologs with e value < 3e-16 c, < 6e-05 d, and < 0.007 e.  
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f For example, Thr-183 of human mitNADK is conserved as a Ser or Thr residue in 108 
animal mitNADK homologs. 
g, h Phosphomimetic substitutions of these residues into Asp or Glu downregulated the 
activity g or had no effect on activity h.  
i The residues had been identified as phosphorylation sites in human mitNADK with 
phosphoproteomics [11,12,13]. 
j All 10 homologs belong to protist mitNADK homologs from Apicomplexa including 
the genera Plasmodium, Theileria, and Babesia. 
k Ser-376 is highly (100%) conserved in the 62 mitNADK homologs from higher 
animals (mammals, birds, reptiles, and fishes). 
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Fig. S3. CD spectrum of the purified enzymes (wild-type [WT] mitNADK, mitNADK 




Fig. S4. Multiple alignments of the representative primary structures of mitNADK homologs. Ser-188, Ser-289, and Ser-376, which downregulated 
NADK activity when they were substituted with phosphomimetic Asp, are in bold. Residues that were detected in human mitNADK are in red. 
 
